FAS and cancer: The AICD of T lymphocytes was a FASL-dependent process and accumulated evidences have demonstrated that the elevated expression of FASL could counterattack FAS-sensitive TILs, which may lead to immune privilege and then weaken the cancer cells' sensitivity to chemotherapy 45.